--- title: 'Industry Daily Summary: What Happened on October 16, 2026' headline: AstraZeneca and insitro sign AI drug-discovery deal worth up to $1.5 billion description: Lakefront sold five preclinical CAR-T programs to Armed Cell as Mankind Pharma agreed to take a 70% stake in the buyer. url: https://thebench.bio/news/industry/2026-10-16 topic: industry date: '2026-10-16' covers: - '2026-10-16' date_published: '2026-10-16T12:04:24Z' date_modified: '2026-10-16T12:04:24Z' tags: - Industry - Software - Research sources: 6 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on October 16, 2026 **AstraZeneca and insitro sign AI drug-discovery deal worth up to $1.5 billion** Lakefront sold five preclinical CAR-T programs to Armed Cell as Mankind Pharma agreed to take a 70% stake in the buyer. ## Today in brief AstraZeneca and insitro signed a drug-discovery deal for MASH and cardiomyopathies, with about $1.46 billion in potential milestone payments. [1] [2] Lakefront sold five preclinical CAR-T assets to Armed Cell for €8 million upfront. Mankind Pharma agreed to buy 70% of Armed Cell for €48 million. [3] ## AstraZeneca and insitro target liver and heart diseases with AI partnership AstraZeneca and insitro will use insitro’s AI platform to identify targets and develop potential medicines for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. [1] [2] AstraZeneca will pay $40 million upfront and could owe about $1.46 billion in development and commercial milestones for exclusive worldwide rights to selected programs. [1] [2] insitro may also receive single-digit royalties on sales if a program reaches the market. [1] [2] The company says its Virtual Human platform analyzes human and cellular data to identify disease biology and possible causal drivers. [1] [2] AstraZeneca will lead clinical development and regulatory work on selected programs, while insitro advances targets toward development candidates. [2] The programs remain at the discovery stage, with no candidate or clinical data disclosed. [2] The partnership adds MASH discovery work to AstraZeneca’s existing effort in the disease, including AZD2389, a small-molecule inhibitor in Phase II testing. [1] AstraZeneca discontinued another MASH candidate, AZD2693, after weak Phase II results. [1] ## Lakefront sells five CAR-T programs as Mankind takes control of Armed Cell Lakefront Biotherapeutics sold five preclinical CAR-T assets to Armed Cell Therapeutics for €8 million upfront. [3] Mankind Pharma separately agreed to pay €48 million for a 70% stake in Armed Cell. [3] Lakefront could receive up to $230 million in regulatory and commercial milestone payments, plus a low-single-digit royalty on sales. [3] Armed Cell said the portfolio includes lead candidates for non-Hodgkin lymphoma and small-cell lung cancer. [3] Armed Cell said the CAR-T designs use multiple targets intended to limit cancer cells’ ability to evade recognition, along with human-protein payloads meant to support immune-cell persistence and activity in tumors. [3] All five assets remain preclinical. Lakefront has not announced when they might enter human trials. [3] The assets originated at Galapagos, which changed its name to Lakefront in May after pursuing a spinout of its cell-therapy programs. [4] [5] Lakefront is also developing gamgertamig, a T-cell engager for autoimmune disease, and expects registrational studies to start in 2027. [3] ## Also worth knowing - Evotec named Joanna Holbrook chief scientific officer, effective November 1. AL-S Pharma now aims to start a Phase 3 trial of AP-101 in 2027, later than its earlier target of late 2026. Sibylla Biotech, Integra Therapeutics, and TETRAPHARM also announced leadership changes. [6] ## The day in numbers - **$40 million**: AstraZeneca’s upfront payment to insitro for the discovery and licensing collaboration. [1] [2] - **About $1.46 billion**: Potential development and commercial milestone payments in the AstraZeneca-insitro deal. [1] [2] - **5**: Preclinical CAR-T assets Lakefront sold to Armed Cell. [3] - **70%**: Stake in Armed Cell Mankind Pharma agreed to acquire. [3] ## Also published - [Genentech documentary celebrates 50th anniversary of biotech](), Bio.News - [The next big shake-up in the GLP-1 market? (Part 1 of 3)](), Labiotech ## Sources 1. [AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership ](), Pharmaceutical Technology, 2026-10-16 2. [AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion](), Pharmaceutical Executive, 2026-10-15 3. [Lakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startup](), European Biotechnology, 2026-10-16 4. [Stoffels, Kremer land at Armed Cell, take rights to ex-Galapagos programs](), BioCentury, 2026-10-15 5. [Belgian startup revives Galapagos CAR-T research](), BioPharma Dive, 2026-10-15 6. [Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs](), European Biotechnology, 2026-10-16 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: